Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content


01/01/2015 -  

500 STEMI patients, randomised 1:3 vs Kaname BMS, primary endpoint TVF 12M. Ongoing.

Designed to:

  • confirm safety and efficacy of Ultimaster drug eluting stent used in STEMI patients by proving superiority in efficacy and non-inferiority in safety versus bare metal stent
  • generate further evidence for benefits of primary PCI with DES in patients with STEMI
  • generate further evidence for benefits of bioresorbable polymer


Study Design

  • randomized (3:1) Ultimaster vs Kaname, single blind
  • 500 patients with acute STEMI
  • 16 sites
  • 5 countries
  • Triple primary endpoint at 1 (safety), 6 (efficacy) and 12 months (safety/efficacy)
  • Secondary endpoints: clinical, procedural, device related, angiographic...

Triple primary endpoint

MASTER - Triple primary endpoint
  • Safety at 1 month:
    composite of all-cause death, recurrent MI, unplanned infarct related artery revascularization, stroke,
    definite stent thrombosis or major bleeding
  • Efficacy at 6 months:
    In-stent late loss in a subset of 100 patients
  • Safety/efficacy at 12 months:
    Target Vessel Failure (TVF), a composite endpoint (cardiac death and MI not clearly attributable to a non-target vessel and clinically driven Target Vessel Revascularisation)

Clinical Follow-up